Emma Ciafaloni MD

Neurology•Rochester, NY

Neuromuscular Medicine, Vascular Neurology

Associate Professor, Neurology, University of Rochester School of Medicine & Dentistry

Join to View Full Profile

601 Crittenden BlvdRochester, NY 14642
Phone+1 585-275-4568
Fax+1 585-273-1254

Education & Training

Duke University HospitalResidency, Neurology, 1996 - 1998
University of Milan Faculty of MedicineClass of 1989
Duke University HospitalFellowship, Neuromuscular Medicine (Neurology)

Certifications & Licensure

NY State Medical License 2002 - 2026
NC State Medical License 1999 - 2003
VA State Medical License 2001 - 2002
American Board of Psychiatry and Neurology Neurology
American Board of Psychiatry and Neurology Neuromuscular Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy Start of enrollment: 2006 Jun 01
Completed
Phase 3
Characteristics of Andersen-Tawil Syndrome Start of enrollment: 2007 Nov 01
Completed
Finding the Optimum Regimen for Duchenne Muscular Dystrophy Start of enrollment: 2013 Jan 01
Completed
Phase 3
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis Start of enrollment: 2014 May 01
Completed
Phase 2
Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy Start of enrollment: 2021 Mar 03
Completed
Phase 2, Phase 3
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) Start of enrollment: 2021 Oct 27
COMPLETED
PHASE3
Roles: Principal Investigator
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) Start of enrollment: 2023 May 31
RECRUITING
PHASE3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

1 citations
Prophylactic Use of Cardiac Medications and Survival in Duchenne Muscular Dystrophy.
Kristin M Conway, Shiny Thomas, Tahereh Neyaz, Emma Ciafaloni, Joshua R Mann
Muscle & Nerve. 2025-04-01
12 citations
AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial.
Jerry R Mendell, Francesco Muntoni, Craig M McDonald, Eugenio M Mercuri, Emma Ciafaloni
Nature Medicine. 2025-01-01
Latent factors underlying the symptoms of adult-onset myotonic dystrophy type 1 during the clinical course.
Yanan Zhang, Bailey Wallace, Bo Cai, Nicholas Johnson, Emma Ciafaloni
Orphanet Journal of Rare Diseases. 2024-11-01

Journal Articles

Implementation of Duchenne Muscular Dystrophy Care Considerations
Emma Ciafaloni, Christopher Cunniff, AAP News

Authored Content

Implementation of Duchenne Muscular Dystrophy Care ConsiderationsJuly 2018

Press Mentions

Recommendations for Clinical Trial Design in Duchenne Muscular Dystrophy: Emma Ciafaloni, MDOctober 2nd, 2022
COVID-19: Guidelines for Myasthenia Gravis Management and Other Neuromuscular DisordersMay 21st, 2020
Where There Is Debate on the ‘Persuasive Evidence’ That Exon-Skipping Therapies Work for Duchenne Muscular DystrophyAugust 15th, 2019
Join now to see all

Grant Support

Trial To Assess The Efficacy &Safety Of MMF In Subjects With Myasthenia GravisNational Center For Research Resources2005
Causes Of Excessive Sleepiness In Myotonic DystrophyNational Center For Research Resources2004–2005
A Clinical Trial Of Cellcept In The Treatment Of Myasthenia GravisNational Center For Research Resources2004–2005

Professional Memberships

American Academy of Neurology - AAN
Member